Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
Authors' conclusion
Diverse methods have been reported as IFN-I assays and these differ in what elements or aspects of IFN-I pathway activation they measure and how.
Study context
- Population
- Reports of type I IFN and rheumatic and musculoskeletal diseases, three databases
- Participants
- 276 papers
- Outcome
- Methods used to measure IFN-I pathway activation (of 412 methods)
Methodological detailsinforming EULAR points to consider, EULAR task force consensus terminology, 10 037 abstracts screened; 276 fulfilled eligibility criteria
- Informing EULAR points to consider
- EULAR task force consensus terminology
- 10 037 abstracts screened; 276 fulfilled eligibility criteria
Recommendations
As reported in the abstract
- qPCR
- 121
- Immunoassays
- 101
- Microarray
- 69
- Reporter cell assay
- 38
- DNA methylation
- 14
- Flow cytometry
- 14
- Cytopathic effect assay
- 11
- RNA sequencing
- 9
- Plaque reduction assay
- 8
- Nanostring
- 5
- Bisulphite sequencing
- 3
Further findings
Validity, reliability and feasibility of assays
- Concurrent validity (correlation with other IFN assays) presented
- n=150/412
- Reliability data provided (variable)
- 13
- Gene expression and immunoassays considered most feasible
Original publication
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open. Published 2 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →